For citations:
Semenov N.N., Fedyanin M.Y., Zhukova L.G., Khatkov I.E., Stroyakovsky D.L., Pokataev I.A. Results of using Pembrolizumab and Nivolumab, immune checkpoint inhibitors (ICIs), in third-line therapy for patients with metastatic gastric cancer. Experience of Moscow oncology service. Siberian journal of oncology. 2025;24(3):93-102. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-3-93-102